Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19 - PubMed (original) (raw)
Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19
Rongrong Jiang et al. Drug Metab Pharmacokinet. 2013.
Free article
Abstract
The present study investigated the inhibitory effect of cannabidiol (CBD), a major constituent of marijuana, on the catalytic activity of cytochrome P450 2C19 (CYP2C19). (S)-Mephenytoin 4'-hydroxylase activities of human liver microsomes (HLMs) and recombinant CYP2C19 were inhibited by CBD in a concentration-dependent manner (IC₅₀ = 8.70 and 2.51 µM, respectively). Omeprazole 5-hydroxylase and 3-O-methylfluorescein O-demethylase activities in recombinant CYP2C19 were also strongly inhibited by CBD (IC₅₀ = 1.55 and 1.79 µM, respectively). Kinetic analysis for inhibition revealed that CBD showed a mixed-type inhibition against (S)-mephenytoin 4'-hydroxylation by recombinant CYP2C19. To clarify the structural requirements for CBD-mediated CYP2C19 inhibition, the effects of CBD-related compounds on CYP2C19 activity were examined. Olivetol inhibited the (S)-mephenytoin 4'-hydroxylase activity of recombinant CYP2C19 with the IC₅₀ value of 15.3 µM, whereas d-limonene slightly inhibited the activity (IC₅₀ > 50 µM). The inhibitory effect of CBD-2'-monomethyl ether (IC₅₀ = 1.88 µM) on CYP2C19 was comparable to that of CBD, although the inhibitory potency of CBD-2',6'-dimethyl ether (IC₅₀ = 14.8 µM) was lower than that of CBD. Cannabidivarin, possessing a propyl side chain, showed slightly less potent inhibition (IC₅₀ = 3.45 µM) as compared with CBD, whereas orcinol and resorcinol did not inhibit CYP2C19 activity at all. These results indicate that CBD caused potent CYP2C19 inhibition, in which one free phenolic hydroxyl group and the pentyl side chain of CBD may play important roles.
Similar articles
- Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Yamaori S, et al. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5. Drug Metab Dispos. 2011. PMID: 21821735 - Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Yamaori S, et al. Life Sci. 2011 Apr 11;88(15-16):730-6. doi: 10.1016/j.lfs.2011.02.017. Epub 2011 Feb 26. Life Sci. 2011. PMID: 21356216 - Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Yamaori S, et al. Drug Metab Pharmacokinet. 2012;27(3):294-300. doi: 10.2133/dmpk.dmpk-11-rg-107. Epub 2011 Dec 13. Drug Metab Pharmacokinet. 2012. PMID: 22166891 - Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.
Yamaori S, Okushima Y, Masuda K, Kushihara M, Katsu T, Narimatsu S, Yamamoto I, Watanabe K. Yamaori S, et al. Biol Pharm Bull. 2013;36(7):1197-203. doi: 10.1248/bpb.b13-00183. Biol Pharm Bull. 2013. PMID: 23811569 - Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.
Yamaori S, Okushima Y, Yamamoto I, Watanabe K. Yamaori S, et al. Chem Biol Interact. 2014 May 25;215:62-8. doi: 10.1016/j.cbi.2014.03.007. Epub 2014 Mar 22. Chem Biol Interact. 2014. PMID: 24667653
Cited by
- Liver Transcriptomic Profiles of Ruminant Species Fed Spent Hemp Biomass Containing Cannabinoids.
Irawan A, Bionaz M. Irawan A, et al. Genes (Basel). 2024 Jul 22;15(7):963. doi: 10.3390/genes15070963. Genes (Basel). 2024. PMID: 39062742 Free PMC article. - Metabolism and liver toxicity of cannabidiol.
Chen S, Li Y, Li X, Wu Q, Puig M, Moulin F, Gingrich J, Guo L. Chen S, et al. J Environ Sci Health C Toxicol Carcinog. 2024;42(3):238-254. doi: 10.1080/26896583.2024.2366741. Epub 2024 Jun 21. J Environ Sci Health C Toxicol Carcinog. 2024. PMID: 38904421 Free PMC article. Review. - Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.
Johnson K, Weldon AJ, Burmeister MA. Johnson K, et al. Front Psychiatry. 2024 Apr 23;15:1386263. doi: 10.3389/fpsyt.2024.1386263. eCollection 2024. Front Psychiatry. 2024. PMID: 38716117 Free PMC article. Review. - Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
Coates S, Bardhi K, Lazarus P. Coates S, et al. Pharmaceutics. 2024 Mar 18;16(3):418. doi: 10.3390/pharmaceutics16030418. Pharmaceutics. 2024. PMID: 38543313 Free PMC article. - Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.
Bardhi K, Coates S, Chen G, Lazarus P. Bardhi K, et al. Pharmaceutics. 2024 Feb 7;16(2):243. doi: 10.3390/pharmaceutics16020243. Pharmaceutics. 2024. PMID: 38399297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases